Plain-English translation of NCT05655702 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a community-based tuberculosis screening and prevention program can reduce the disease among people who inject drugs in Hai Phong, Vietnam. Researchers will use four rounds of health surveys where participants answer questions about symptoms, get chest X-rays, and provide sputum samples. For some participants with latent (inactive) tuberculosis infection, the trial will also test whether a 12-dose medication called isoniazid/rifapentine (3HP) is safe, acceptable, and effective at preventing active disease.
People who inject drugs face a much higher risk of tuberculosis than the general population — up to 40 times higher in this study — yet they often have difficulty accessing care. This medication was designed to prevent active tuberculosis in people with latent infection, but researchers need to understand whether it works well and is practical for this vulnerable community.
You likely qualify if…
You likely don't qualify if…
You will participate in one of four rounds of screening surveys. During the first and final rounds, you will answer questions about tuberculosis symptoms, have a chest X-ray, and provide a sputum sample (coughed-up mucus) for testing. In the middle two rounds, you will receive a shorter screening. All participants will also have a tuberculin skin test to check for latent tuberculosis. If you have latent infection, you may be invited to join an additional study to receive the 12-dose preventive medication over 12 weeks and have your experience and health monitored.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Vietnam
Sponsor
ANRS, Emerging Infectious Diseases
Collaborators
Haiphong University of Medicine and Pharmacy, Expertise France
Enrollment target
~4,000 participants
Started
October 2023
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marion BONNETON
PCCI UMR 1058 - INSERM, Univ Montpellier, EFS, Montpellier, Franc
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.